Kutumbetov L 1
1. Breaking the Barrier: SARS-CoV-2 Infections in Wild and Companion Animals and Their Implications for Public Health
2. Phylogenetic analysis of a 2024 Sheeppox virus isolate from the Almaty region of Kazakhstan and investigation of its pathogenicity in merino sheep
3. Coding Complete Genome Sequence of the SARS-CoV-2 Virus Strain, Variant B.1.1, Sampled from Kazakhstan
4. Retention of lumpy skin disease virus in Stomoxys spp (Stomoxys calcitrans, Stomoxys sitiens, Stomoxys indica) following intrathoracic inoculation, Diptera: Muscidae
5. The combined effects of temperature and relative humidity parameters on the reproduction of Stomoxys species in a laboratory setting
6. Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up
7. Development and Preclinical Evaluation of a Lyophilized Vaccine Against Equine Herpesvirus Type 4 (EHV-4)
8. Investigation of the Pathogenesis of Lumpy Skin Disease Virus in Indigenous Cattle in Kazakhstan
9. Safety and Immunogenicity of the Live Attenuated Vaccine QazCOVID-Live Against Coronavirus Infection COVID-19: Pre-Clinical Study Results
10. SARS-CoV-2 Delta Variant Does Not Sustain Replication in Companion Dogs: Insights from an Experimental Infection Model
11. Susceptibility and Transmission Dynamics of Peste des Petits Ruminants Virus in Domestic and Wild Ruminants: Experimental Insights from Kazakhstan
12. Complete genome sequence of SARS-CoV-2 isolated from a dog in Kazakhstan
13. Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19
14. Pre-Clinical Safety and Immunogenicity Study of a Coronavirus Protein-Based Subunit Vaccine for COVID-19
15. Near-Complete Genome Sequence of a SARS-CoV-2 Variant B.1.1.7 Virus Strain Isolated in Kazakhstan
16. Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan
17. Development of the Inactivated QazCovid-in Vaccine: Protective Efficacy of the Vaccine in Syrian Hamsters
1